Background: Diffusion-weighted MRI imaging (DWI) is frequently employed, particularly to assess organs such as breast, prostate, ovaries, liver, and pancreas. Aim: The present study aimed to assess the diffusion MRI role in characterization benign breast lesions from malignant breast lesions. Patients and Methods: This prospective study was conducted on 260 breasts lesions of 200 patients in the Department of Radiology, Jinnah Hospital Lahore and DHQ Hospital, Vihari from January 2021 to September 2022. Females (15 and 75 years) with breast lesion of diameter (>1cm) were enrolled. About 60 patients underwent breast MRI with contrast and DWI. The remaining 140 patients underwent DWI came for sonomammography. ADC values (b-vale 0-300, 0-600, and 0-1000) for all lesions were computed for differentiating the benign and malignant lesions. Benign and malignant breast lesions were categorized based on ADC values (1.3-1.5 mm2/s) and (0.85-1.1 mm2/s) respectively. Results: Of the total 260 breast lesions, the incidence of benign and malignant breast lesions based on ADC values were 192 (73.8%) and 68 (22.2%) respectively. About 4 lesions were benign based on ADC value but were proven malignant after intervention. This approach of detecting malignant lesions based on ADC values has a specificity 100%, sensitivity 97.22%, positive prediction value 100%, and negative prediction value 99%. The ADC value of benign versus malignant breast lesions at b-value (0-300), (0-600), and (0-1000) were 1.56±0.23 vs. 0.82±0.21, 1.54±0.09 vs. 0.89±0.17, and 1.52±0.16 vs. 0.84±0.18 respectively. Conclusion: The present study demonstrated that DWI for breast lesions had a good sensitivity and specificity for distinguishing benign from malignant lesions. Keywords: Breast lesions, DWI, MRI, benign lesions, malignant lesions
Background and Aim: Acute pelvic pain during pregnancy can be challenging to identify and manage. Ultrasound is still the most often utilized imaging modality for pregnant and postpartum women. The present study aimed to evaluate the ultrasonography role in various causes of pelvic pain in first trimester of pregnancy. Patients and Methods: This descriptive cross-sectional study was carried out on 286 pelvic pain pregnant women of first trimester. It was conducted in the department of Radiology in collaboration with Obstetrics and Gynecology department of Jinnah Hospital, Lahore from March 2022 to November 2022. Pregnant women with pelvic pain during early pregnancy were enrolled. Patient’s demographic details i.e. age, gestational age, HC, molar pregnancy, CRL, Fibroid, FHR, and bleeding on ultrasound were recorded. Data analysis was done using SPSS version 27. . Results: The overall mean age of participants was 26.84±2.86 years (18 to 45 years). Patients distribution based on age were as follows: 76 (26.6%) in 18-25 years, 156 (54.5%) in 26-35 years, and 54 (18.9%) in 36-45 years. Out of the total 286 pregnant women, the prevalence of bleeding, fibroids, cyst, and ectopic pregnancy was 92 (32.2%), 42 (14.7%), 56 (19.6%), and 18 (6.3%) respectively. The prevalence of pelvic pain causes such as Corpus luteal cyst, Dermoid Cyst, Ectopic pregnancy, Intramural Fibroid, Submucosal Fibroid, and sub serosal fibroid was 38/54 (70.4%), 26/34 (76.5%), 22/28 (78.6%), 1/20 (5%), 4/10 (40%), and 1/22 (4.5%) respectively. Conclusion: Bleeding was the most dominant finding followed by cyst and fibroids in pregnant women with chronic pelvic pain during early pregnancy. Pelvic pain in the early pregnancy can be difficult to treat. In assessing these individuals, ultrasound is a critical imaging modality. Keywords: Pelvic pain, ultrasonography, causes, first trimester, pregnancy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.